Alembic, Breckenridge and Mylan have failed to persuade the US Court of Appeals for the Federal Circuit that the US Patent and Trademark Office (USPTO) wrongly upheld the validity of several claims in the sole listed patent protecting UCB’s Vimpat (lacosamide) epilepsy treatment.
The three generics firms had appealed against a decision reached by the USPTO’s Patent Trial and Appeal Board (PTAB) that...